Product
Radium-223 dichloride
Aliases
radium-223, Radium-223, radium-223 dichloride, Radium-223 dichloride (Xofigo, BAY 88-8223), Radium-223 dichloride (Xofigo, BAY88-8223)
Name
radium-223
11 clinical trials
1 drug
11 indications
Indication
Prostate CancerIndication
Castration-ResistantIndication
Castration-resistant Prostate CancerIndication
Bone metastasesIndication
cancerIndication
Non-Small Cell LungIndication
MetastasisIndication
Breast NeoplasmsClinical trial
Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) PatientsStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)Status: Completed, Estimated PCD: 2018-02-15
Clinical trial
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAHStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone MetastasesStatus: Active (not recruiting), Estimated PCD: 2022-01-06
Clinical trial
Safety and Effectiveness of Xofigo® (Radium-223 Dichloride) in Routine Clinical Practice Settings in TaiwanStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium-223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment.Status: Active (not recruiting), Estimated PCD: 2023-10-10
Clinical trial
China Radium-223 Safety and Effectiveness stuDy In Real World mCRPC paTientsStatus: Terminated, Estimated PCD: 2023-04-28
Clinical trial
An Open-label, Multicenter, Phase 1/2 Study of Radium-223 Dichloride in Combination With Pembrolizumab in Participants With Stage IV Non-small Cell Lung CancerStatus: Terminated, Estimated PCD: 2021-04-14
Clinical trial
A Double Blind, Randomised, Dose Finding, Repeat Dose, Phase II, Multicentre Study of Alpharadin® for the Treatment of Patients With Hormone Refractory Prostate Cancer and Skeletal MetastasesStatus: Completed, Estimated PCD: 2008-12-01
Clinical trial
A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone MetastasesStatus: Completed, Estimated PCD: 2020-01-22
Clinical trial
Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm EvaluationStatus: Active (not recruiting), Estimated PCD: 2024-08-02